# (Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia

> **NCT05236634** · NA · UNKNOWN · sponsor: **Assiut University** · enrollment: 120 (estimated)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Phosphodiesterase 5 Inhibitors
- **DRUG:** Alpha Blockers
- **DRUG:** Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors

## Key facts

- **NCT ID:** NCT05236634
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05236634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05236634, "(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-09-12 from https://api.ai-analytics.org/clinical/NCT05236634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*